Further advancement for MS stem cell treatments

There is more good news from leading stem cell biotech Advanced Cell Technology (ACT) on preclinical rodent studies using stem cells to treat mice with an MS-like condition.

They published a new paper in the journal Stem Cell Reports entitled “Human ESC-Derived MSCs Outperform Bone Marrow MSCs in the Treatment of an EAE Model of Multiple Sclerosis” by Wang, et al.

Mesenchymal stem cells (MSCs) derived from human embryonic stem (hES) cells, termed hES-MSCs by the authors) were able to substantially reduce symptoms of a Multiple Sclerosis (MS)-like disease in mice.

While the control mice were severely disabled by the MS modeling condition including paralysis, those treated with the hES-MSCs were significantly healthier. In some cases this difference was dramatic as shown in the video above (Courtesy of Dr. Xiaofang Wang and Dr. Ren-he Xu, ImStem Biotechnology, Inc.) where we see a hES-MSC-treated MS model mouse running around and a control severely ill.

ADVERTISEMENT

Read the full, original story: Advanced Cell Technology (ACT) Revs Up Pre-Clinical Studies for MS

Outbreak Daily Digest
Biotech Facts & Fallacies
GLP Podcasts
Infographic: Here’s where GM crops are grown around the world today

Infographic: Here’s where GM crops are grown around the world today

Do you know where biotech crops are grown in the world? This updated ISAAA infographics show where biotech crops were ...
News on human & agricultural genetics and biotechnology delivered to your inbox.
glp menu logo outlined

Newsletter Subscription

* indicates required
Email Lists
Send this to a friend